Tag

Venkata Rao Sadhanala

2 articles

Venmax Drugs Reports No Preferential Issue Fund Deviation

Venmax Drugs confirms no deviation in use of ₹20.05 crore raised via preferential issue of fully convertible equity warrants. Funds utilized as per original objects: ₹8.37 crore for working capital an

Venmax Drugs Q1 FY27 Net Profit ₹11.66 Lakh

Board approved unaudited Q1 FY27 results with net profit of ₹11.66 lakhs and reviewed by auditors PPKG & Co. Approved forfeiture of 7,80,001 partly paid-up share warrants due to non-payment of ₹15 per